Group 1 - Siyuan Electric reported a total operating revenue of 21.205 billion yuan for 2025, a year-on-year increase of 37.18%, with a net profit attributable to shareholders of 3.163 billion yuan, up 54.35% year-on-year [1] - VisiOn expects a negative net profit for 2025, indicating a loss in operating performance [2] - Chongqing Steel anticipates a net loss of 2.5 billion to 2.8 billion yuan for 2025, which is an improvement from a net loss of 3.196 billion yuan in the previous year [3] - Lianfa Co. forecasts a net profit of 280 million to 320 million yuan for 2025, representing a year-on-year growth of 38.92% to 58.77% [4] Group 2 - CICC announced that the audit work related to the absorption merger with Dongxing Securities and Xinda Securities has not yet been completed [5] - Dalong Real Estate's subsidiary won a project bid worth 763 million yuan [6] - Zhongchuang Zhiling plans to issue convertible bonds to raise no more than 4.35 billion yuan for various projects [7] - Jintong Co. intends to acquire a 24% stake in Jinsha Molybdenum for 1.731 billion yuan [8] Group 3 - Nami Technology expects a net profit of 128 million to 145 million yuan for 2025, an increase of 54.51% to 75.03% year-on-year [9] - China State Construction reported a new contract total of 4.5458 trillion yuan for 2025, a 1% increase year-on-year [12] - China Metallurgical Group's new contract amount for 2025 is expected to decrease by 10.8% to 1.1136 trillion yuan [13] Group 4 - Beiding Co. reported a net profit of 111 million yuan for 2025, a year-on-year increase of 59.05% [14] - Southwest Securities expects a net profit of 1.028 billion to 1.098 billion yuan for 2025, an increase of 47% to 57% [15] - China Eastern Airlines reported a 4.93% year-on-year increase in passenger capacity for December 2025 [20] Group 5 - *ST Aowei's stock may be delisted due to a closing price below par value [21] - Yilian Network expects a net profit of 2.542 billion to 2.648 billion yuan for 2025, a decrease of 0% to 4% year-on-year [22] - Huochen Co. anticipates a net profit of 420 million to 540 million yuan for 2025, recovering from a loss of 2 million yuan in the previous year [17] Group 6 - Guoli Electronics expects a net profit of 68 million to 80 million yuan for 2025, an increase of 124.89% to 164.57% [28] - Jinchuan Group forecasts a net profit of 11 billion to 12 billion yuan for 2025, a year-on-year increase of 73.57% to 89.34% [41] - Triangle Tire plans to invest 3.219 billion yuan in a new tire project in Cambodia [42]

Core Viewpoint - The company Shapais (603168) has received approval from the National Medical Products Administration for the drug Diflunisal, which is now considered to have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The drug Diflunisal is indicated for the treatment of rheumatoid arthritis, osteoarthritis, and various mild to moderate pain [1]

Core Viewpoint - The company, Zhejiang Shapuaisi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the supplementary application of Diflunisal tablets, indicating a significant advancement in its product portfolio [1]. Group 1: Product Approval - The company has obtained the approval notice for Diflunisal tablets, with notification numbers 2026B00097 and 2026B00098 [1]. - Diflunisal tablets have passed the consistency evaluation of generic drug quality and efficacy, which is crucial for market entry [1]. Group 2: Indications and Applications - The approved Diflunisal tablets are indicated for rheumatoid arthritis, osteoarthritis, and various mild to moderate pain conditions, expanding the therapeutic options available [1]. Group 3: R&D Investment - As of the date of the announcement, the total research and development investment for the Diflunisal tablet project amounts to approximately 7.1492 million RMB [1].

浙江莎普爱思药业股份有限公司 关于获得二氟尼柳片 《药品补充申请批准通知书》的公告 证券代码：603168 证券简称：莎普爱思 公告编号：临 2026-003 剂型：片剂 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 规格：0.25g 近日，浙江莎普爱思药业股份有限公司（以下简称"公司"、"莎普爱思"）收到 国家药品监督管理局核发的二氟尼柳片的《药品补充申请批准通知书》（通知书编号： 2026B00097、2026B00098），现将有关信息公告如下： 一、《药品补充申请批准通知书》主要内容 审批结论：根据《中华人民共和国药品管理法》、《国务院关于改革药品医疗器械 审评审批制度的意见》（国发【2015】44号）和《关于仿制药质量和疗效一致性评价工 作有关事项的公告》（2017年第100号）的规定，经审查，本品视同通过仿制药质量和 疗效一致性评价。 药品名称：二氟尼柳片 药品名称：二氟尼柳片 注册分类：化学药品 上市许可持有人：浙江莎普爱思药业股份有限公司 药品生产企业：浙江莎普爱思药业股份有限公司 剂型：片剂 规格：0.5g ...

莎普爱思公告，近日，公司收到国家药品监督管理局核发的二氟尼柳片的《药品补充申请批准通知 书》。药品名称为二氟尼柳片，剂型为片剂，规格为0.25g和0.5g，注册分类为化学药品，上市许可持有 人和药品生产企业均为公司。审批结论为视同通过仿制药质量和疗效一致性评价。 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临2026-002 公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工作，尽快披露2025 年度业绩预告。公司2025年度财务数据请以公司正式披露的经审计后的2025年年度报告为准。 浙江莎普爱思药业股份有限公司 2025年度业绩预亏的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 经浙江莎普爱思药业股份有限公司(以下简称"公司")财务部门初步测算，公司预计2025年度归属于母公 司所有者的净利润为负值，主要系公司预计需计提商誉减值准备导致。 登录新浪财经APP 搜索【信披】查看更多考评等级 特此公告。 浙江莎普爱思药业股份有限公司董事会 2026年1月13日 本次业绩预告提示性情况未经注册会计师审计。公司将在后续年报编制工作中与年审会计师保持沟通， 如在审计过程中出现可能影响业绩预告准确性的重大变化，公司将及时履行信息披露义务。 公司指定的信息披露媒体为《中国证券报》《上海证券报》《证券时报》《证券日报》及上海证券交易 所网站(www. ...

Core Viewpoint - The company Shapais (603168) anticipates a negative net profit attributable to shareholders for the year 2025, primarily due to expected goodwill impairment provisions [1] Financial Performance Summary - In 2024, the company reported total operating revenue of 484 million yuan, a year-on-year decrease of 24.96% [1] - The net profit attributable to shareholders for 2024 was a loss of 123 million yuan, compared to a profit of 25.41 million yuan in the previous year [1] - The non-recurring net profit for 2024 was a loss of 107 million yuan, compared to a loss of 4.01 million yuan in the previous year [1] - The net cash flow from operating activities for 2024 was 25.67 million yuan, a year-on-year decrease of 38.13% [1] - For the first three quarters of 2025, the company achieved revenue of 351 million yuan and a net profit attributable to shareholders of 27.63 million yuan [1] Market Position - As of January 12, the company's stock price was 7.74 yuan per share, with a total market capitalization of 2.896 billion yuan [1]

北京商报讯（记者 丁宁）1月12日晚间，莎普爱思（603168）发布公告称，经公司财务部门初步测算， 公司预计2025年度归属净利润为负值，主要系公司预计需计提商誉减值准备导致。 莎普爱思表示，公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工 作，尽快披露2025年度业绩预告。公司2025年度财务数据请以公司正式披露的经审计后的2025年年度报 告为准。 ...

莎普爱思（603168）(603168.SH)发布公告，经公司财务部门初步测算，公司预计2025年度归属于母公 司所有者的净利润为负值，主要系公司预计需计提商誉减值准备导致。 ...

证券代码：603168 证券简称：莎普爱思 公告编号：临 2026-002 浙江莎普爱思药业股份有限公司 2025 年度业绩预亏的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 经浙江莎普爱思药业股份有限公司(以下简称"公司")财务部门初步测算，公司预计 2025年度归属于母公司所有者的净利润为负值，主要系公司预计需计提商誉减值准备导 致。 公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算 工作，尽快披露2025年度业绩预告。公司2025年度财务数据请以公司正式披露的经审计 后的2025年年度报告为准。 本次业绩预告提示性情况未经注册会计师审计。公司将在后续年报编制工作中与年 审会计师保持沟通，如在审计过程中出现可能影响业绩预告准确性的重大变化，公司将 及时履行信息披露义务。 公司指定的信息披露媒体为《中国证券报》《上海证券报》《证券时报》《证券日 报》及上海证券交易所网站(www.sse.com.cn)，有关公司信息均以公司在上述指定媒体 披露信息为准，敬请广大投资者注意投资风险。 特此公 ...